Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

RMD open

Showing results (951-960 of 1,920) with videos related to

Pageof 192
Sort By:
RMD Open|October 29, 2015
Belimumab in systemic lupus erythematosusAndreia Vilas-Boas, Sandra A Morais, David A Isenberg
RMD Open|October 29, 2015
Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatmentB Fautrel, H W Nab, Y Brault, et al.
RMD Open|October 29, 2015
Depression is a stronger predictor of the risk to consider work disability in early arthritis than disease activity or response to therapyJohanna Callhoff, Katinka Albrecht, Georg Schett, et al.
RMD Open|October 29, 2015
Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agentA Woerner, F Uettwiller, I Melki, et al.
RMD Open|October 29, 2015
The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countriesA Finckh, D Neto, F Iannone, et al.
RMD Open|October 29, 2015
The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic regionX Mariette, J Vencovsky, O Lortholary, et al.
RMD Open|October 29, 2015
The H2 blocker famotidine suppresses progression of ossification of the posterior longitudinal ligament in a mouse modelYujiro Maeda, Kenichi Yamamoto, Akira Yamakawa, et al.
RMD Open|October 29, 2015
Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposureP Mease, A Deodhar, R Fleischmann, et al.
RMD Open|October 29, 2015
Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatologyM P T de Wit, T K Kvien, L Gossec
RMD Open|November 5, 2015
Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012Dörte Huscher, Katja Thiele, Martin Rudwaleit, et al.
Pageof 192

Showing results (951-960 of 1,920) with videos related to

Sort By:
Pageof 192
RMD Open|October 29, 2015
Belimumab in systemic lupus erythematosusAndreia Vilas-Boas, Sandra A Morais, David A Isenberg
RMD Open|October 29, 2015
Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatmentB Fautrel, H W Nab, Y Brault, et al.
RMD Open|October 29, 2015
Depression is a stronger predictor of the risk to consider work disability in early arthritis than disease activity or response to therapyJohanna Callhoff, Katinka Albrecht, Georg Schett, et al.
RMD Open|October 29, 2015
Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agentA Woerner, F Uettwiller, I Melki, et al.
RMD Open|October 29, 2015
The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countriesA Finckh, D Neto, F Iannone, et al.
RMD Open|October 29, 2015
The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic regionX Mariette, J Vencovsky, O Lortholary, et al.
RMD Open|October 29, 2015
The H2 blocker famotidine suppresses progression of ossification of the posterior longitudinal ligament in a mouse modelYujiro Maeda, Kenichi Yamamoto, Akira Yamakawa, et al.
RMD Open|October 29, 2015
Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposureP Mease, A Deodhar, R Fleischmann, et al.
RMD Open|October 29, 2015
Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatologyM P T de Wit, T K Kvien, L Gossec
RMD Open|November 5, 2015
Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012Dörte Huscher, Katja Thiele, Martin Rudwaleit, et al.
Pageof 192